Vitiligo is an acquired hypopigmentation of the skin due to a progressive selective loss of melanocytes; A study on performance and interpretability.
Furthermore, ritlecitinib is currently under clinical trials for oral treatment of active vitiligo. A study on performance and interpretability.
World Vitiligo Day, Observed Annually On June 25Th, Aims To Shed Light On This Often Misunderstood Condition ( 1 Trusted Source.
Keep me logged in on this computer.
The Vitiligo Treatment Market Size Attained A Value Of Usd 538.90 Million In 2023, Driven By The Rising Disease Prevalence And The Discovery Of Advanced Diagnostics.
Vitiligo is a chronic skin condition characterized by the loss of pigment, resulting in irregular white patches on the skin.
Images References :
Ruxolitinib Is The First Approved In Vitiligo Therapy.
Emerging research on oral therapeutics for vitiligo.
Fda Approval Means Better Access To Vitiligo Treatment.
Advantages and disadvantages, indications for use and outcomes.